** Shares of drug developer GH Research GHRS.O rise 90% to $20.14 premarket
** Co's therapy for treatment-resistant depression meets main goal of mid-stage trial by reducing the severity of the disease as measured on a widely used scale
** GHRS says 57.5% of patients on the therapy, GH001, had less severe disease at 8 days
** GH001 also meets all secondary goals of the trials, GHRS adds
** GHRS rose 20.7% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。